Vir Biotechnology Inc Stock News

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Inve...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be prov...

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits. The post Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment appeared first on Investor's Business Daily.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiti...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors sec...

VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.